South Korea's Hanmi Pharmaceutical and its global partner Spectrum Pharmaceuticals are moving closer to the commercialization of the oral pan-HER inhibitor poziotinib in the US with the submission by the US biotech of a Phase II breast cancer protocol to the FDA as part of an IND application. But the partners are having to fine-tune their development strategy given what is a crowded sector.
SEOUL - Hanmi Pharmaceutical Co. Ltd. and its partner Spectrum Pharmaceuticals Inc. are set to begin a Phase II study in the US for oral pan-HER inhibitor poziotinib which the South Korean company licensed out to the US firm earlier this year.
Spectrum, a US biotechnology company with a primary focus in hematology and oncology, has submitted an IND application to the...